Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Tracy C KuoAmy ChenOns HarrabiJonathan T SockoloskyAnli ZhangEmma SangalangLaura V DoyleSteven E KauderDanielle FontaineSangeetha BolliniBora HanYang-Xin FuJanet SimJaume PonsHong I WanPublished in: Journal of hematology & oncology (2020)
The in vitro and in vivo antitumor activity of hAB21 broadly recapitulates that of CD47 targeted therapies despite differences in ligand expression, binding partners, and function, validating the CD47-SIRPα axis as a fundamental myeloid checkpoint pathway and its blockade as promising therapeutic intervention for treatment of human malignancies.
Keyphrases
- immune response
- dendritic cells
- dna damage
- cell cycle
- acute myeloid leukemia
- bone marrow
- endothelial cells
- binding protein
- poor prognosis
- randomized controlled trial
- nk cells
- toll like receptor
- induced pluripotent stem cells
- cancer therapy
- cell proliferation
- hiv testing
- long non coding rna
- drug delivery
- men who have sex with men